Trial Profile
A Phase 2 Study of Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Temozolomide (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 08 Apr 2021 Status changed from active, no longer recruiting to completed.
- 29 Apr 2020 Planned End Date changed from 1 Jul 2019 to 1 Dec 2020.
- 13 Jul 2016 Planned number of patients changed from 30 to 20.